Internal Medicine, Endocrinology, Diabetes, & Metabolism · Spring Hill, FL
NPI
1801032529
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
14690 Spring Hill Dr Ste 206
Spring Hill, FL, 34609
Phone (352) 799-4206
Groups this clinician bills Medicare through
Medicare paid, 2024
$61K
954 services
Medicare patients, 2024
275
Average age 73
Drug cost, 2024
$3.2M
6,488 prescriptions
Company payments, 2025
$337
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sumbul A Ali was code 99214 (office e&m - established), 465 times for 233 patients. In total Sumbul A Ali billed 954 services in 15 codes, and Medicare paid $61K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 465 | 233 | $90.30 | $42K |
| 95251 Test - Miscellaneous | Office | 250 | 108 | $25.88 | $6,469 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 144 | 119 | $12.63 | $1,819 |
| 99204 Office E&M - New | Office | 47 | 47 | $124.63 | $5,857 |
| 99222 Hospital E&M - Initial | Facility | 11 | 11 | $102.11 | $1,123 |
By year: 2022 $73K for 1,041 services; 2023 $76K for 1,044 services; 2024 $61K for 954 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sumbul A Ali prescribed most often to Medicare patients was Ozempic (Semaglutide), with 469 prescriptions and refills. In total Sumbul A Ali wrote 6,488 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 469 | 751 | 108 | $724K |
| Levothyroxine Sodium Generic | 467 | 1,312 | 151 | $6,806 |
| Metformin Hcl Generic | 392 | 1,013 | 126 | $2,577 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 389 | 925 | 128 | $71K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 348 | 929 | 145 | $47K |
| Novolog Flexpen Insulin Aspart | 257 | 619 | 102 | $92K |
| Jardiance Empagliflozin | 230 | 514 | 67 | $293K |
| Tresiba Flextouch U-100 Insulin Degludec | 199 | 491 | 62 | $178K |
| Methimazole Generic | 171 | 482 | 59 | $2,064 |
| Mounjaro Tirzepatide | 148 | 227 | 36 | $247K |
| Glipizide Generic | 147 | 406 | 59 | $1,208 |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 141 | 335 | 43 | $111K |
| Rosuvastatin Calcium Generic | 133 | 369 | 39 | $1,546 |
| Metformin Hcl Er Metformin Hcl | 123 | 345 | 47 | $1,389 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 111 | 170 | 22 | $115K |
Brand drugs: 3,445 claims; generic drugs: 2,166 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sumbul A Ali $337 ($337 in general payments such as food, travel and fees) from 13 companies. The largest payer was Sequel Med Tech, LLC with $48.34.
| Company | Payments | Amount |
|---|---|---|
| Sequel Med Tech, LLC | 2 | $48.34 |
| Mannkind Corporation MNKD | 1 | $42.5 |
| Insulet Corporation PODD | 2 | $38.86 |
| Medtronic, Inc. MDT | 1 | $33.27 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $24.04 |
| Radius Health, Inc. | 1 | $21.88 |
| IBSA Pharma Inc. | 1 | $21.7 |
| Abbott Laboratories ABT | 1 | $20.9 |
| Ascensia Diabetes Care Us Inc. | 1 | $20.4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19.51 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.